A Phase I Study of Single Agent Talazoparib (BMN 673) in Advanced Cancer Patients With Hepatic and Renal Dysfunction
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Talazoparib (Primary)
- Indications Adenocarcinoma; Breast cancer; Gastric cancer; Head and neck cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 14 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 14 Apr 2017 Planned initiation date changed from 1 Jul 2016 to 1 Jun 2016.
- 09 Oct 2015 New trial record